RTP Mobile Logo
Visiting Professors: Lung Cancer Edition, Issue 1, 2011
Released March 2011

Featuring Dr Mark A Socinski’s perspective on a day spent visiting patients with lung cancer in the clinic of community oncologist Dr Matthew R Skelton. (Audio Content)

CE Disclosures and Faculty Information


    Lung cancer is increasingly recognized as a heterogeneous group of tumor types. Not long ago, it was clinically sufficient to make a differentiation between small cell lung cancer and non-small cell lung cancer (NSCLC). Published results from recent trials have led to the approval of three different agents for NSCLC in the maintenance setting, with only one of these being for the broad population of patients with NSCLC. Individualized treatment decisions are increasingly driven by genetic biomarkers in addition to histological subtype and patient-specific characteristics. Early incorporation of palliative care strategies has also demonstrated an effect on patient outcomes. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists must be well informed of these advances.

    To provide clinicians with therapeutic strategies for addressing the disparate needs of patients with lung cancer, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading lung cancer investigators and community oncologists as they explore the intricacies of clinical decision-making. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.


    • Use case-based learning and shared clinical insight to provide comprehensive and compassionate oncology care.
    • Refine current treatment approaches through the appraisal of therapeutic advances in lung cancer.
    • Summarize clinical trial results with adjuvant chemotherapy in NSCLC.
    • Recall the rationale for and design of clinical trials investigating VEGF inhibitors as part of initial treatment and maintenance therapy for nonsquamous NSCLC.
    • Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NSCLC.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should review the CME information ad listen to to the audio MP3s.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Skelton had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SocinskiData and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals; Paid Research: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc; Speakers Bureau: Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Sanofi-Aventis.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Genentech BioOncology & OSI Oncology and Lilly USA LLC.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last Review Date: February 2011
    Expiration Date: February 2012

Acknowledge and close

Listen to audio: